Robert G Dullea
Overview
Explore the profile of Robert G Dullea including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
126
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aspnes G, Coffey S, Darout E, Dechert-Schmitt A, Dullea R, Kamlet A, et al.
Bioorg Med Chem Lett
. 2023 Jun;
92:129394.
PMID: 37379958
Our previous work on the optimization of a new class of small molecule PCSK9 mRNA translation inhibitors focused on empirical optimization of the amide tail region of the lead PF-06446846...
2.
Li W, Ward F, McClure K, Chang S, Montabana E, Liras S, et al.
Nat Struct Mol Biol
. 2019 Jun;
26(6):501-509.
PMID: 31160784
The drug-like molecule PF-06446846 (PF846) binds the human ribosome and selectively blocks the translation of a small number of proteins by an unknown mechanism. In structures of PF846-stalled human ribosome...
3.
Londregan A, Wei L, Xiao J, Lintner N, Petersen D, Dullea R, et al.
J Med Chem
. 2018 Jun;
61(13):5704-5718.
PMID: 29878763
The optimization of a new class of small molecule PCSK9 mRNA translation inhibitors is described. The potency, physicochemical properties, and off-target pharmacology associated with the hit compound (1) were improved...
4.
Lintner N, McClure K, Petersen D, Londregan A, Piotrowski D, Wei L, et al.
PLoS Biol
. 2018 Apr;
16(4):e1002628.
PMID: 29664898
[This corrects the article DOI: 10.1371/journal.pbio.2001882.].
5.
McClure K, Piotrowski D, Petersen D, Wei L, Xiao J, Londregan A, et al.
Angew Chem Int Ed Engl
. 2017 Oct;
56(51):16218-16222.
PMID: 29073340
Targeting of the human ribosome is an unprecedented therapeutic modality with a genome-wide selectivity challenge. A liver-targeted drug candidate is described that inhibits ribosomal synthesis of PCSK9, a lipid regulator...
6.
Lintner N, McClure K, Petersen D, Londregan A, Piotrowski D, Wei L, et al.
PLoS Biol
. 2017 Mar;
15(3):e2001882.
PMID: 28323820
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in regulating the levels of plasma low-density lipoprotein cholesterol (LDL-C). Here, we demonstrate that the compound PF-06446846 inhibits translation of...
7.
Chen C, Stock J, Liu X, Shi J, Van Deusen J, DiMattia D, et al.
Drug Metab Dispos
. 2008 Jun;
36(9):1840-5.
PMID: 18556442
We generated the organic anion transporting polypeptide (Oatp) 1b2 knockout (KO) mouse model and assessed its utility to study hepatic uptake using model compounds: cerivastatin, lovastatin acid, pravastatin, simvastatin acid,...